BPC-157 + TB-500 (Wolverine Blend)

What is in the vial

Each vial contains equal masses of two unrelated sequences. BPC-157 is a fifteen-amino-acid partial sequence of body protection compound, a protein characterised in gastric juice. TB-500 is a seven-amino-acid acetylated fragment covering residues 17 to 23 of thymosin beta-4, the region associated with G-actin binding. They share no sequence homology and are studied through different proposed mechanisms.

The BPC-157 component

The TB-500 component

TB-500 is examined mainly in cell-migration and cytoskeletal contexts: scratch and transwell assays with keratinocytes and endothelial cells, corneal and dermal wound models, and cardiac remodelling studies in mice. The proposed rationale for pairing it with BPC-157 is that the two are studied at different stages of a repair process rather than at the same target.

Why researchers use a pre-blend

State of the evidence

No published controlled study establishes that the combination outperforms either peptide alone, and human data for both sequences are minimal. Both appear on the World Anti-Doping Agency prohibited list. The blend is offered strictly as a research reagent, with no dosing or protocol guidance.

Keep the sealed blend vial at −20 °C, dry and shielded from light, and let it reach room temperature before opening so condensation does not reach the powder. Reconstitute by running bacteriostatic or sterile water slowly down the inner wall; swirl gently until the cake clears and never shake or vortex, as foaming damages both peptides. Because the vial holds two sequences at a fixed ratio, any dilution applies to both simultaneously, so record concentrations per component. Hold the reconstituted solution at 2–8 °C, protected from light, and aliquot before freezing.